Urogen Pharma Current Ratio 2016-2021 | URGN

Urogen Pharma current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Urogen Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.14B $0.02B 7.37
2021-03-31 $0.09B $0.02B 5.47
2020-12-31 $0.12B $0.02B 5.39
2020-09-30 $0.13B $0.02B 7.34
2020-06-30 $0.13B $0.02B 7.91
2020-03-31 $0.12B $0.01B 8.58
2019-12-31 $0.15B $0.02B 7.63
2019-09-30 $0.16B $0.01B 11.35
2019-06-30 $0.19B $0.01B 16.14
2019-03-31 $0.25B $0.01B 24.16
2018-12-31 $0.10B $0.01B 7.59
2018-09-30 $0.11B $0.01B 12.42
2018-06-30 $0.12B $0.01B 15.18
2018-03-31 $0.13B $0.01B 23.26
2017-12-31 $0.07B $0.01B 10.59
2017-09-30 $0.08B $0.01B 16.33
2017-06-30 $0.08B $0.01B 15.77
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2015-12-31 $0.02B $0.00B 8.58
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.012B
UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57